Alpha-Msh (11-13) Acetate Salt:Exports & Compliance White Paper 2026

I. Executive Summary

Alpha-MSH (11-13) acetate salt (CAS 67727-97-3) is the C-terminal tripeptide fragment Lys-Pro-Val of alpha-melanocyte-stimulating hormone, supplied to laboratories as a Research Use Only (RUO) peptide. It has no approved therapeutic indication in any jurisdiction. It is not a medicinal product, it is not for human or veterinary administration, and it is emphatically not a cosmetic, self-tanning or consumer product. Buyers and suppliers alike should treat the commercial perimeter as the primary risk in this category, not an afterthought.

A compliance boundary note is essential: alpha-MSH analogues belonging to the melanotan family are unapproved substances regulated in several jurisdictions, including the European Union, the United Kingdom, the United States, China and Australia, and enforcement activity has targeted consumer tanning and injectable channels. This tripeptide must not be marketed, repacked, reformulated or resold into the consumer tanning, cosmetic or injectable channel under any circumstances. Legitimate demand is confined to in-vitro receptor and structure-activity research, analytical standard use and regulated custom-synthesis projects conducted by qualified institutions.

From a CDMO standpoint the value drivers are peptide content and salt-form control, impurity profiling by LC-MS/MS, residual trifluoroacetic acid and counter-ion analysis, water content and lyophilisation quality, and cold-chain integrity. Commercial programmes also require documented Know-Your-Customer screening, a written end-use declaration, a stated policy of refusing non-qualified orders, and explicit WADA and anti-doping awareness, because melanocortin-pathway analogues are a recognised screening topic in sport and in regulated supply chains. No dosing, administration or performance guidance is provided in this paper and none should be supplied with the material.

II. Product Deep Dive: Molecular Mechanisms and Production Evolution

2.1 Physicochemical Properties and Mechanisms

The tripeptide sequence is Lys-Pro-Val, with a free N-terminus on lysine and a free carboxylic acid on valine; the free peptide has a relative molecular mass of approximately 342.4 daltons, and the acetate salt carries one or more equivalents of acetic acid depending on the number of protonated basic sites and the isolation conditions. The lysine side chain provides the dominant positive charge and much of the aqueous solubility, while the proline-valine segment contributes conformational constraint and hydrophobic contact surface. In receptor research the fragment is used to probe the contribution of the C-terminal region of alpha-MSH to melanocortin receptor recognition.

• Sequence and conformational character: proline restricts the backbone and favours a turn-like presentation, so the fragment behaves very differently from a flexible Lys-Val dipeptide in binding assays. This is precisely why the fragment is studied: it isolates the C-terminal contribution to affinity and selectivity across melanocortin receptor subtypes in vitro, and it is used only as a research probe, not as a therapeutic agent.
• Salt form, peptide content and stability: the acetate salt is preferred for research material because residual trifluoroacetate can perturb cell-based assays, so salt exchange is a specification item rather than a convenience. Certificates must state peptide content separately from gross mass, because lyophilised peptides contain water and counter-ion; acetate or trifluoroacetate content, water by Karl Fischer and appearance are stability-indicating parameters, and the solid is hygroscopic and best stored frozen and desiccated.

2.2 Synthesis and Manufacturing Technologies

Production is standard peptide chemistry executed under quality discipline. Because this is a short sequence, the manufacturing challenge is not chain assembly but impurity resolution: deletion sequences, incompletely deprotected species, and residual cleavage by-products all co-elute near the target and require high-resolution purification and orthogonal analytics.

• Solid-phase peptide synthesis: Fmoc/tBu chemistry on a suitable resin with sequential coupling, capping and deprotection gives the protected resin-bound tripeptide, which is cleaved and globally deprotected before purification. Coupling efficiency, racemisation risk at each residue and complete Fmoc removal are the process parameters controlled in development, and the cleavage cocktail composition is chosen to protect the lysine side chain and the C-terminal acid.
• Purification, salt exchange and isolation: preparative reversed-phase HPLC under a developed gradient resolves the target from deletion and by-product peptides; the pooled fraction is then converted to the acetate form by ion-exchange or repeated co-evaporation from dilute acetic acid, quantified for residual trifluoroacetate, sterile-filtered where required, and isolated by lyophilisation with a controlled cycle and residual-solvent and water limits.

2.3 Core Application Matrix

• Melanocortin receptor and structure-activity research: used in vitro by academic and biotech laboratories to map receptor-binding contributions, to compare subtype selectivity, and to calibrate signalling assays in melanocortin biology. All such work is non-clinical, and material is supplied with a Research Use Only statement.
• Analytical standard and method development: serves as a reference material for LC-MS/MS quantitation, for stability and forced-degradation studies, for amino-acid-analysis and peptide-content method validation, and as a system-suitability standard in peptide analytical laboratories.
• Custom synthesis and CDMO programmes: contracted by pharmaceutical, biotech and reagent customers for analogue series, labelled variants, scale-up campaigns and GMP-aligned supply, delivered under confidentiality with structured tech transfer and defined containment and occupational-exposure controls.

III. Global Market Supply-Demand Landscape and Export Trends

3.1 Demand Drivers and Market Shifts

Legitimate demand follows peptide-therapeutics research spending: melanocortin biology is an active field in metabolic, dermatological and receptor-pharmacology programmes, and the growth of outsourced peptide synthesis has moved purchasing from individual investigators to centralised procurement at CROs and reagent distributors. Demand is therefore small in grams but high in documentation intensity, and it is highly sensitive to compliance posture - customers qualify suppliers on their screening and refusal policies as much as on their chromatograms.

3.2 Capacity Distribution and Export Flows

Peptide manufacturing capacity is concentrated in China and India for cost-competitive synthesis and purification, with China supplying a large share of global research-peptide volume, while the United States and Europe host high-end peptide CDMOs and GMP-capable facilities serving regulated programmes. Trade flows run from Asian synthesis sites to Western distributors, reagent brands and research institutions, with an increasing share shipped directly to CROs under confidentiality agreements and end-use declarations rather than through open catalogue channels.

3.3 Market Bifurcation and Pricing Dynamics

The market splits cleanly between RUO catalogue material sold in milligram vials at high unit price with minimal documentation, and GMP-aligned or qualified campaign material where price per gram rises with analytical depth, containment requirements and regulatory support. Peptide content basis is the most common source of apparent price discrepancy: two quotes for the same sequence can differ simply because one is quoted on gross lyophilised mass and the other on peptide content, so buyers must normalise before comparing.

IV. In-depth Analysis of Global Compliance and Regulatory Barriers

For a research peptide with no approved indication, compliance is less about product authorisation and more about perimeter discipline: correct labelling, honest end-use screening, chemical-inventory obligations and, where campaigns escalate, GMP and ICH expectations. Suppliers who treat these as paperwork risk enforcement exposure and the loss of institutional customers.

4.1 European Market: REACH, CLP, and Sector-Specific Directives

• Unapproved-substance perimeter in the EU and UK: alpha-MSH analogues of the melanotan family are not authorised medicinal products and have been the subject of regulatory and enforcement action when placed on consumer or injectable channels; the tripeptide must be supplied only as Research Use Only laboratory material, never as a cosmetic ingredient, food supplement or injectable product, with SDS and labelling making that restriction explicit.
• Chemical and quality obligations: importers must confirm REACH (EC) No 1907/2007 registration, PPORD or exemption status for the substance and hold a current CLP (EC) No 1272/2008 SDS; where a customer requires regulated material, campaigns are run under ICH Q7 and Q11 principles with ICH Q1A stability, Q3C residual-solvent and Q3D elemental-impurity assessment, supported by ISO 9001 quality systems.

4.2 North American Market: TSCA, EPA, and FDA Regulations

• FDA and consumer-channel prohibition: the peptide has no approved therapeutic indication and is not an FDA-approved drug; supply must be labelled Research Use Only, not for human or veterinary use, and must not be directed to cosmetic, tanning or injectable consumer channels. Where a customer's programme is regulated, material is produced in a GMP-aligned campaign with appropriate FDA-facing documentation rather than as catalogue RUO stock.
• TSCA, screening and anti-doping obligations: TSCA inventory or exemption status must be documented for import, while buyers should operate documented KYC, end-use declaration and institutional-credential checks. WADA and anti-doping relevance is a real compliance-screening topic for melanocortin-pathway analogues, and suppliers should maintain a written refusal policy for non-qualified or consumer-directed orders.

4.3 The Critical Hurdle: Quality Control and Safety Limits

V. Green Trade Barriers and ESG in Manufacturing

Peptide manufacturing is solvent-intensive, and ESG pressure arrives from two directions: customer procurement questionnaires on solvent use and waste, and chemical legislation restricting the polar aprotic solvents that peptide chemistry historically depended upon.

5.1 Carbon Footprint and Circular Economy

The footprint is driven by dimethylformamide and N-methylpyrrolidone use in coupling and deprotection, by acetonitrile consumption in preparative and analytical HPLC, and by energy-intensive lyophilisation and frozen logistics. Serious programmes measure process mass intensity, substitute greener coupling solvents where chemistry permits, recover acetonitrile and dimethylformamide by distillation, report Scope 1 and 2 energy with Scope 3 freight and raw-material emissions, and treat peptide-containing waste streams under documented containment before disposal.

5.2 Sustainable Sourcing and Traceability

Buyers ask for documented origin of the protected amino acids, typically fermentation-derived L-amino acids with non-animal-origin and TSE/BSE-free statements, together with REACH-compliant solvent sourcing and ISO 14001-certified sites. Traceability means lot genealogy from resin and amino-acid lots through cleavage, purification, salt exchange and fill, with retained samples and a documented change-control history that lets a customer's investigation be closed within days rather than weeks.

VI. Supply Chain Resilience and Export Logistics

The material is a hygroscopic lyophilised solid shipped frozen, so logistics failures destroy value silently: the vial arrives, the certificate looks correct, and only the customer's assay reveals degradation. Logistics must therefore be designed with the same rigour as the synthesis.

6.1 Packaging Standards and Moisture/Contamination Control

• Desiccated amber vial with inert headspace: amber glass vials with PTFE-lined closures, filled from a single homogeneous lyophilisation batch, closed under dry nitrogen or dry air, and packed in a heat-sealed foil pouch with desiccant and humidity indicator. Water content, appearance and peptide content should be tested on retention samples drawn from the commercial vial configuration.
• Containment and occupational hygiene: weighing, subdivision and dispensing of the neat peptide are conducted under containment appropriate to the assigned occupational exposure band and health-based exposure limit, with local exhaust, glove-box or isolator handling, documented cleaning and waste inactivation, and personnel training records available for customer audit.

6.2 Dangerous Goods Identification and Transit Protocols

The peptide itself is ordinarily not classified as dangerous for road, sea or air transport, but frozen shipments introduce regulated elements: dry ice is UN1845, Class 9, and air freight must follow IATA packing instruction 954 with correct net-mass marking and documentation, while refrigerated lanes require qualified 2-8 °C packaging validated for the lane and season. Specify -20 °C storage, define acceptable excursion limits, place calibrated data loggers in every shipment, and operate a written excursion investigation procedure so that any temperature deviation is assessed against stability data before the material is released to a research customer.

VII. Enterprise Global Expansion Strategy Guide

Growth in this category is won by trust and documentation discipline rather than by price. The following measures are the ones that determine whether an institutional customer will qualify a supplier at all.

1. Operate a documented compliance perimeter: implement KYC screening, institutional credential verification, a signed end-use declaration, a written policy refusing non-qualified, consumer, cosmetic or injectable-channel orders, and maintain records of decisions taken; state the Research Use Only status on quotation, label, certificate and website.
2. Offer a two-grade analytical architecture: a fast RUO line with HPLC purity, LC-MS identity, peptide content, water and residual trifluoroacetate data, and a GMP-aligned campaign line applying ICH Q7, Q11, Q1A, Q3C and Q3D with validated methods, impurity identification and full lot genealogy.
3. Protect the relationship with tech transfer discipline: run custom programmes under mutual confidentiality with segregated campaign records, provide a structured technology-transfer package to the receiving laboratory, define containment and occupational-exposure expectations in the quality agreement, and guarantee frozen cold-chain performance with documented excursion handling.

VIII. Conclusion

Alpha-MSH (11-13) acetate salt is a small, well-defined research peptide whose commercial reality is shaped almost entirely by governance. The chemistry is routine for a competent peptide CDMO; what distinguishes credible suppliers is peptide-content honesty, impurity and counter-ion transparency, frozen cold-chain reliability, and an uncompromising refusal to serve consumer, cosmetic, tanning or injectable channels. Institutions buy from suppliers whose compliance posture they can show to their own regulators.

Through 2026, the organisations that succeed with CAS 67727-97-3 will be those combining Fmoc solid-phase capability, high-resolution preparative purification and acetate salt-form control with ICH-aligned quality systems, containment discipline, KYC screening and WADA-aware end-use governance. Those four pillars, not nominal synthesis capacity, define participation in the legitimate research market for this material.

IX. Industry Resource Connection and Supplier Ecosystem

Powered by Guidechem

This white paper is exclusively compiled by the Guidechem Intelligence Team based on global customs data, regulatory databases, and industry research. Guidechem is a leading global B2B chemical platform, dedicated to connecting global buyers with verified, high-quality manufacturers.

Guidechem Global Alpha-MSH (11-13) acetate salt Supplier Ecosystem List

Relying on Guidechem's extensive global database, we have mapped the core participants in the current global Alpha-MSH (11-13) acetate salt supply chain:

• China - peptide synthesis and purification capacity: Chinese peptide manufacturers supply a large share of global research-peptide volume, combining Fmoc solid-phase synthesis, preparative HPLC and lyophilisation at competitive cost with growing analytical depth and ISO 9001 quality systems. Buyers should verify peptide-content reporting practice, residual trifluoroacetate control, salt-form conversion capability and, critically, the supplier's written end-use screening and refusal policy before qualifying.
• United States - peptide CDMOs, distributors and institutional demand: the US ecosystem combines GMP-capable peptide CDMOs serving regulated programmes with reagent distributors and CRO procurement teams that define specifications and hold vendor qualification files. TSCA documentation, RUO labelling discipline, institutional KYC and anti-doping awareness are standard expectations, and confidentiality and tech-transfer quality often decide award more than price.
• European Union - compliance framing and qualified research supply: EU participants emphasise REACH and CLP documentation, SDS quality, ISO 9001 and ISO 14001 certification, and strict Research Use Only framing reinforced by enforcement against unapproved melanotan-family products in consumer channels. European customers typically require full lot genealogy, containment and occupational-exposure documentation, and a supplier that can evidence refusals of non-qualified orders.